Lorlatinib: First Global Approval

@article{Syed2018LorlatinibFG,
  title={Lorlatinib: First Global Approval},
  author={Yahiya Y. Syed},
  journal={Drugs},
  year={2018},
  volume={79},
  pages={93-98}
}
Lorlatinib is an oral small molecule inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer (NSCLC). Based on results from a phase I/II trial, lorlatinib received approval in Japan in September 2018 and in the USA in November 2018 for the treatment of ALK-positive NSCLC. This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this… 
Evaluating entrectinib as a treatment option for non-small cell lung cancer
TLDR
Entrectinib has been well studied across many tumor types, including NSCLC with ALK, ROS1, and NTRK rearrangements, and the drug has demonstrated favorable properties with oral administration, prolonged response duration, high intracranial efficacy, and a favorable toxicity profile.
Brigatinib as a treatment of ALK-positive non-small cell lung cancer
TLDR
An up-to-date overview of the current and evolving clinical data regarding the biology of the disease, the emerging clinical decision-making and the targeted therapy options in advanced NSCLC harboring ALK translocation is presented, especially focusing on the activity of brigatinib.
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
TLDR
Both oral and IV lorlatinib were well-tolerated in healthy participants and oral lorLatinib is highly bioavailable after oral administration.
A user's guide to lorlatinib.
TLDR
A User's Guide to Lorlatinib reviews the mechanism of action, pharmacology and clinical trial data, and covering the management of adverse events, has been prepared to be a practical reference tool to both clinicians and basic researchers.
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer
TLDR
This drug discovery case history focuses on the key studies that led to the preclinical discovery and development of osimertinib and focuses on published preclinical studies by scientists from AstraZeneca and highlight key events in the clinical development.
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
TLDR
Lorlatinib is highly brain penetrant and exhibits autoinduction after multiple dosing, and there appears to be no inherent differences in lorLatinib PK between healthy subjects and cancer patients, or between Asian and non-Asian patients.
Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC
TLDR
This work focuses on anaplastic lymphoma kinase (ALK), a member of the receptor tyrosine kinase family, as an oncogenic driver in NSCLC, and discusses the available treatment options for ALK-positive NSCLCs with an emphasis on the second-generation ALK inhibitor ceritinib.
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).
TLDR
Lorlatinib, a third-generation ALK inhibitor, has demonstrated activity in the treatment naïve setting and in resistance to crizotinib and second- generation ALK inhibitors, which is associated with the development of ALK resistance mutations, specifically G1202R.
A new ALK inhibitor overcomes resistance to first and secondgeneration inhibitors in NSCLC
  • Yue Lu, Zhenzhen Fan, +26 authors Xianming Deng
  • 2021
More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients
Drug discovery targeting anaplastic lymphoma kinase (ALK).
TLDR
The "proteolysis targeting chimera" (PROTAC) technique has been successfully employed in ALK drug discovery, which opened a promising new avenue for targeted ALK therapies and the mechanism of drug resistance and potential therapeutic strategies to overcome drug resistance are summarized.
...
1
2
3
4
...

References

SHOWING 1-10 OF 19 REFERENCES
First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.
TLDR
Lorlatinib is a 3rd-generation macrocyclic ALK-TKI that demonstrates many advantages over 2nd-generation ALK inhibitors and acts as an ALK/ROS1 inhibitor in clinical settings.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
TLDR
Overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer and safety data for all treated patients (EXP1-6) are presented.
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
TLDR
In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-positive or ROS1-positive NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail.
Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) andALKkinase domain mutations
TLDR
Lorlatinib exhibited antitumor activity across a variety of ALK kinase domain resistance mutations, including the difficult-to-treat ALK G1202R mutation.
Anaplastic Lymphoma Kinase as a Therapeutic Target in Non–Small Cell Lung Cancer
TLDR
Current preclinical and clinical studies are focused on the development of rational therapeutic strategies, including novel ALK inhibitors, as well as rational combination therapies to maximize disease control by delaying or overcoming acquired therapeutic resistance.
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
TLDR
In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain, and sequencing of the resistant tumor revealed an ALK L1198F mutation in addition to the C1156Y mutation.
Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer
The identification of chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene in ~3–5% of non–small cell lung cancer (NSCLC) tissues and the demonstration that the
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
TLDR
The results suggest that PF-06463922 will be highly effective for the treatment of patients with ALK-driven lung cancers, including those who relapsed on clinically available ALK inhibitors because of secondary ALK kinase domain mutations and/or brain metastases.
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
TLDR
In vitro kinase assays and cell-based experiments examining ALK mutations of increasing potency show that PF-06463922 is an effective inhibitor of ALK with greater activity towards ALK neuroblastoma mutants.
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
TLDR
The next-generation ALK/ROS1 inhibitor PF-06463922 exerts unparalleled activity in ALK-driven neuroblastoma models with primary crizotinib resistance and exerts unprecedented activity as a single targeted agent against F1174L and F1245C ALk-mutated xenograft tumors, while also inducing responses in an R1275Q Xenograft model.
...
1
2
...